Dilisym Services, a Simulations Plus company based in North Carolina, on Tuesday announced new software in development to treat heart failure.
Simulations Plus in Lancaster specializes in providing simulation and modeling software to test pharmaceutical efficacy and safety.
Dilisym’s software is sponsored by an unnamed pharmaceutical company and will be available via licensing and consulting for the pharmaceutical industry once completed.
“Building upon our success in developing Dilisym, the industry standard for liver safety modeling, we have applied our (quantitative systems pharmacology) expertise in an expanding array of therapeutic areas including (nonalcoholic steatohepatitis, pulmonary fibrosis) and now heart failure,” Brett Howell, president of Dilisym, said in a statement.
Shares of Simulations Plus (SLP) closed Tuesday up $1.04, or more than 3 percent, to $33.70 on the Nasdaq.